- Home
- FMST vs ACXP Comparison
FMST vs ACXP Comparison
Compare FMST & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMST
- ACXP
- Stock Information
- Founded
- FMST 2005
- ACXP 2017
- Country
- FMST Canada
- ACXP United States
- Employees
- FMST N/A
- ACXP N/A
- Industry
- FMST Other Metals and Minerals
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- FMST Basic Materials
- ACXP Health Care
- Exchange
- FMST Nasdaq
- ACXP Nasdaq
- Market Cap
- FMST 7.1M
- ACXP 8.4M
- IPO Year
- FMST N/A
- ACXP 2021
- Fundamental
- Price
- FMST $3.27
- ACXP $0.43
- Analyst Decision
- FMST
- ACXP Strong Buy
- Analyst Count
- FMST 0
- ACXP 2
- Target Price
- FMST N/A
- ACXP $10.00
- AVG Volume (30 Days)
- FMST 1.2M
- ACXP 18.4M
- Earning Date
- FMST 01-01-0001
- ACXP 08-08-2025
- Dividend Yield
- FMST N/A
- ACXP N/A
- EPS Growth
- FMST N/A
- ACXP N/A
- EPS
- FMST N/A
- ACXP N/A
- Revenue
- FMST N/A
- ACXP N/A
- Revenue This Year
- FMST N/A
- ACXP N/A
- Revenue Next Year
- FMST N/A
- ACXP N/A
- P/E Ratio
- FMST N/A
- ACXP N/A
- Revenue Growth
- FMST N/A
- ACXP N/A
- 52 Week Low
- FMST $0.55
- ACXP $0.30
- 52 Week High
- FMST $5.74
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- FMST 56.55
- ACXP 47.99
- Support Level
- FMST $3.27
- ACXP $0.52
- Resistance Level
- FMST $3.78
- ACXP $0.63
- Average True Range (ATR)
- FMST 0.53
- ACXP 0.09
- MACD
- FMST -0.12
- ACXP 0.00
- Stochastic Oscillator
- FMST 27.69
- ACXP 17.33
About FMST Foremost Lithium Resource & Technology Ltd. Common stock
Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with significant historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.